Adrenal Insufficiency Market Summary

• According to DelveInsight, Adrenal Insufficiency Market is expected to grow at a decent CAGR by 2032.
• Adrenal Insufficiency Companies include Antares Pharma Inc, Citrine (Shanghai) Co Ltd, Crossject SA, Diurnal Group Plc, Eton Pharmaceuticals and others.

Factors affecting Adrenal Insufficiency Market Growth

Rising Incidence of Adrenal Insufficiency

Increasing cases of Addison’s disease and secondary adrenal insufficiency elevate the risk of adrenal crises.

Growing Awareness of Endocrine Disorders

Educational initiatives and physician training enhance early recognition and timely management.

Advancements in Diagnostic Tools

Improved cortisol assays and point-of-care testing support quicker and more accurate diagnosis.

Development of Novel Therapeutics

Availability of synthetic glucocorticoids and advanced hormone replacement therapies expands treatment options.

Increasing Geriatric Population

Older adults with multiple comorbidities are more prone to experiencing adrenal crises.

Expansion of Emergency and Critical Care Services

Enhanced hospital infrastructure and specialized care units ensure rapid intervention during crises.

DelveInsight's "Adrenal Insufficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Adrenal Insufficiency, historical and forecasted epidemiology as well as the Adrenal Insufficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Adrenal Insufficiency market report provides current treatment practices, emerging drugs, Adrenal Insufficiency market share of the individual therapies, current and forecasted Adrenal Insufficiency market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Adrenal Insufficiency treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Adrenal Insufficiency market.

Adrenal Insufficiency Disease Understanding

Adrenal insufficiency is a condition in which the adrenal glands do not produce adequate amounts of essential hormones—primarily cortisol, and in some cases aldosterone. This hormonal deficiency can disrupt metabolism, blood pressure regulation, immune response, and stress management. The disorder may be primary (Addison’s disease), where the adrenal glands are directly affected, or secondary, caused by insufficient ACTH production from the pituitary gland. Symptoms often develop gradually and include fatigue, weight loss, low blood pressure, salt craving, and darkening of the skin. If left untreated, it can lead to a life-threatening adrenal crisis.

Adrenal Insufficiency Diagnosis

Diagnosis of adrenal insufficiency involves a combination of clinical evaluation, laboratory tests, and imaging. Doctors typically assess cortisol and ACTH levels, both at baseline and after stimulation tests such as the ACTH (cosyntropin) stimulation test, which is the gold standard. Additional tests may include electrolyte panels, renin and aldosterone levels, and insulin-induced hypoglycemia testing for secondary causes. Imaging studies like CT or MRI may be used to evaluate the adrenal or pituitary glands depending on the suspected type of insufficiency.

Adrenal Insufficiency Treatment

Treatment focuses on lifelong hormone replacement therapy to restore deficient hormones. Patients with primary adrenal insufficiency usually require glucocorticoids (e.g., hydrocortisone, prednisone) and mineralocorticoids (e.g., fludrocortisone) to regulate sodium and potassium balance. Stress-dose steroids are crucial during illness, surgery, or intense physical stress to prevent adrenal crisis. Managing lifestyle factors, carrying medical alert identification, and patient education on crisis prevention are essential components of long-term care.

Adrenal Insufficiency Epidemiology Analysis

The Adrenal Insufficiency epidemiology section provides insights about the historical and current Adrenal Insufficiency patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Adrenal Insufficiency market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings from Adrenal Insufficiency Epidemiological Analyses and Forecast

• According to Adrenal Insufficiency organization among one million people, between 82-144 are diagnosed with primary and 150-280 with secondary adrenal insufficiency. In children, the genetic forms are more common: congenital adrenal hyperplasia accounts for approx. 70% of adrenal insufficiency, other genetic disorders for approximately 6% and autoimmune disease for only 10-15%.
• Primary adrenal insufficiency (PAI) is rare, with a prevalence of 10–20 persons per 100,000 population and has multiple aetiologies. Although tuberculosis is one of the predominant causes of PAI, nowadays Addison disease and congenital adrenal hyperplasia (CAH) are emerging as the prominent causes of PAI. Addison disease accounts for ~90% of non-CAH cases in industrialized countries.
• According to a study conducted by Regan et al. (2019) timely accurate diagnosis remains a problem for patients with primary adrenal insufficiency in an affluent, well-educated US cohort. Episodes of adrenal crisis are common and replacement steroid treatment is not always effective for patient function.
• In some studies it is found that women are more likely to develop adrenal Insufficiency than males.
• Females are more likely to have a polyglandular form, while isolated adrenal damage is more common in males in the first two decades. By the fourth decade, the isolated form is more common in women.
• The epidemiology of adrenal insufficiency in children is not well-defined. Congenital adrenal hyperplasia (CAH) is the most common etiology of primary adrenal insufficiency in children, occurring once in 14,200 live births.

Adrenal Insufficiency Epidemiology Segmentation

• Total Cases of Adrenal Insufficiency in the US [2020–2034]
• Type-specific Cases of Adrenal Insufficiency in the US [2020–2034]
• Gender-specific Cases of Adrenal Insufficiency in the US [2020–2034]
• Complication-specific Cases of Adrenal Insufficiency in the US [2020–2034]
• Treatable Cases of Adrenal Insufficiency in the US [2020–2034] 

Adrenal Insufficiency Market Recent Developments and Breakthroughs

• In May 2025, Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for KHINDIVI™ (hydrocortisone) Oral Solution as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency.

Adrenal Insufficiency Drug Analysis

The drug chapter segment of the Adrenal Insufficiency market report encloses the detailed analysis of Adrenal Insufficiency marketed drugs and late-stage (Phase-III and Phase-II) Adrenal Insufficiency pipeline drugs. It also helps to understand the Adrenal Insufficiency clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Adrenal Insufficiency Marketed Drugs

ALKINDI SPRINKLE: Diurnal Group

ALKINDI SPRINKLE, developed by Diurnal Group, is a is a corticosteroid indicated as replacement therapy in pediatric patients with adrenocortical
insufficiency.

In May 2015, ALKINDI SPRINKLE received Orphan Drug Designation for the treatment of pediatric adrenal insufficiency (0 through 16 years of age).

Adrenal Insufficiency Emerging Drugs

ATRS-1902: Halozyme Therapeutics

ATRS-1902 is an investigational rescue treatment that uses a proprietary autoinjector to deliver a liquid stable formulation of hydrocortisone.

• In January 2022, Antares Pharma announced that the US FDA granted Fast Track designation for ATRS-1902 for adrenal crisis rescue. The designation was based on Phase I study results, which showed ATRS-1902 (100mg) delivered a comparable pharmacokinetic profile to Solu-Cortef (hydrocortisone for IV or IM injection; 100mg) in 32 healthy adults. ATRS-1902 was also found to be safe and well-tolerated.
• In May 2022, Halozyme Therapeutics announced the successful completion of its acquisition of Halozyme Therapeutics.

ZENEO Hydrocortisone Autoinjector: Eton Pharmaceuticals

ZENEO hydrocortisone autoinjector product candidate is a proprietary needle-free autoinjector under development for the treatment of adrenal crisis.

• In June 2021, the company acquired US marketing rights from Crossject to the ZENEO hydrocortisone autoinjector.
• The company expects to submit a New Drug Application (“NDA”) for the product in 2025, which could allow for FDA approval in 2026.

Adrenal Insufficiency Market Outlook

The Adrenal Insufficiency market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Adrenal Insufficiency market trends by analyzing the impact of current Adrenal Insufficiency therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Adrenal Insufficiency market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Adrenal Insufficiency market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Adrenal Insufficiency market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Adrenal Insufficiency market in 7MM.

The United States: Adrenal Insufficiency Market Outlook

This section provides the total Adrenal Insufficiency market size and market size by therapies in the United States.

EU-5 Countries: Adrenal Insufficiency Market Outlook

The total Adrenal Insufficiency market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan: Adrenal Insufficiency Market Outlook

The total Adrenal Insufficiency market size and market size by therapies in Japan is also mentioned.

Adrenal Insufficiency Drugs Uptake

This section focuses on the rate of uptake of the potential Adrenal Insufficiency drugs recently launched in the Adrenal Insufficiency market or expected to get launched in the market during the study period 2019-2032. The analysis covers Adrenal Insufficiency market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Adrenal Insufficiency Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Adrenal Insufficiency market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Adrenal Insufficiency Clinical Trial Activities

The Adrenal Insufficiency market report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Adrenal Insufficiency key players involved in developing targeted therapeutics.

Adrenal Insufficiency Pipeline Development Activities

The Adrenal Insufficiency market report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Adrenal Insufficiency emerging therapies.

Adrenal Insufficiency Market Access and Reimbursement

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL Views on Adrenal Insufficiency

To keep up with current Adrenal Insufficiency market trends, we take KOLs and SMEs ' opinion working in the Adrenal Insufficiency domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Adrenal Insufficiency market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Adrenal Insufficiency Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Adrenal Insufficiency Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Adrenal Insufficiency Market Report

• The report covers the descriptive overview of Adrenal Insufficiency, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Adrenal Insufficiency epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Adrenal Insufficiency is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Adrenal Insufficiency market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adrenal Insufficiency market

Adrenal Insufficiency Market Report Highlights

• In the coming years, the Adrenal Insufficiency market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Adrenal Insufficiency R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Adrenal Insufficiency. The launch of emerging therapies will significantly impact the Adrenal Insufficiency market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Adrenal Insufficiency
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Adrenal Insufficiency Market Report Insights

• Adrenal Insufficiency Patient Population
• Therapeutic Approaches
• Adrenal Insufficiency Pipeline Analysis
• Adrenal Insufficiency Market Size
• Adrenal Insufficiency  Market Trends
• Adrenal Insufficiency Market Opportunities
• Impact of upcoming Adrenal Insufficiency Therapies

Adrenal Insufficiency Market Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Adrenal Insufficiency Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Adrenal Insufficiency Market
• Adrenal Insufficiency Drugs Uptake

Adrenal Insufficiency Market Report Assessment

• Current Adrenal Insufficiency Treatment Practices
• Unmet Needs
• Adrenal Insufficiency Pipeline Product Profiles
• Adrenal Insufficiency Market Attractiveness
• Adrenal Insufficiency Market Drivers
• Adrenal Insufficiency Market Barriers

Key Questions Answered in the Adrenal Insufficiency Market Report

Adrenal Insufficiency Market Insights

• What was the Adrenal Insufficiency drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Adrenal Insufficiency market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Adrenal Insufficiency market size during the forecast period (2019-2032)?
• At what CAGR, the Adrenal Insufficiency market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Adrenal Insufficiency market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Adrenal Insufficiency market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the Adrenal Insufficiency market dynamics and subsequent analysis of the associated trends?

Adrenal Insufficiency Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Adrenal Insufficiency?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Adrenal Insufficiency patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Adrenal Insufficiency in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Adrenal Insufficiency?
• Out of all 7MM countries, which country would have the highest prevalent population of Adrenal Insufficiency during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current options for the Adrenal Insufficiency treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Adrenal Insufficiency in the USA, Europe, and Japan?
• What are the Adrenal Insufficiency marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many Adrenal Insufficiency companies are developing therapies for the treatment of Adrenal Insufficiency?
• How many therapies are in-development by each company for Adrenal Insufficiency treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Adrenal Insufficiency treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Adrenal Insufficiency therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Adrenal Insufficiency and their status?
• What are the current challenges faced in Adrenal Insufficiency drug development?
• What are the key designations that have been granted for the emerging therapies for Adrenal Insufficiency?
• What are the global historical and forecasted Adrenal Insufficiency market?

Reasons to buy the Adrenal Insufficiency Market Report

• The Adrenal Insufficiency market report will help in developing business strategies by understanding trends shaping and driving the Adrenal Insufficiency market
• To understand the future market competition in the Adrenal Insufficiency market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Adrenal Insufficiency in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming adrenal insufficiency companies in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Adrenal Insufficiency market
• To understand the future market competition in the Adrenal Insufficiency market